ARE Stock Analysis — Alexandria Real Estate Equities
Sector: REITs
AI Verdict
At 70.3x forward earnings with negative growth and an overbought RSI, you're paying a premium the numbers don't yet support, and the moat only helps if demand for biotech lab space rebounds.
Competitive Moat
Alexandria specializes in life science and biotech campuses clustered in innovation hubs, offering lab space that is expensive and time-consuming for tenants to replicate. This high switching cost and embedded tenant relationships in regulated industries create a defensible niche within commercial real estate.
Summary
ARE stands out for its focus on purpose-built lab space in top biotech clusters, a rare asset class in commercial real estate.
Where It Stands
Despite a -37.84% 1-year return and -13.0% trailing revenue growth, the stock trades at 70.3x next year's earnings—nearly triple the REIT sector norm—while its RSI of 77.0 signals overbought territory.
Key Metrics
- RSI: 77 — Overbought
- Forward P/E: 70.3x
- PEG Ratio: 0.70
- Revenue Growth: -0.1%
- Market Cap: $9.2B
- Dividend Yield: 0.05%
- 1-Year Return: -37.84%
- 52-Week High: $88.24
- 52-Week Low: $39.41
Analyst Consensus
3 Buy · 14 Hold · 8 Sell (25 analysts)
Bull Case
With a trailing PEG ratio of 0.70, the stock's high P/E is mathematically justified by its historical growth rate if that growth can resume.
Bear Case
If the forward P/E compresses from 70.3x toward the REIT sector average, the stock could lose more than half its value even before considering the -13.0% revenue contraction.
Catalyst to Watch
Watch for leasing updates or tenant retention rates—any sign of stabilized or growing occupancy could support the premium multiple.